METHODS AND COMPOSITIONS FOR TREATING SUBJECTS EXPOSED TO VESICANTS AND OTHER CHEMICAL AGENTS
Disclosed herein are methods and compositions comprising adherent stromal cells.
1 . A method of reducing a morbidity in a subject exposed to a vesicant, comprising administering to said subject a pharmaceutical composition comprising adherent stromal cells (ASC), thereby reducing a morbidity in a subject exposed to a vesicant.
2 . The method of claim 1 , wherein said morbidity comprises chronic inflammation, pulmonary fibrosis, pulmonary hypertension, or pancytopenia.
3 . A method of reducing a mortality in a subject exposed to a vesicant, comprising administering to said subject a pharmaceutical composition comprising adherent stromal cells (ASC), thereby reducing a mortality in a subject exposed to a vesicant.
4 . The method of claim 1 , wherein said vesicant is selected from Lewisite, a mustard compound, and an organic arsenic compound.
5 . A method of reducing central nervous system (CNS) damage in a subject exposed to an organophosphate agent, comprising administering to said subject a pharmaceutical composition comprising adherent stromal cells (ASC), thereby reducing CNS damage in a subject exposed to an organophosphate agent.
6 . The method of claim 5 , wherein said CNS damage results from CNS inflammation.
7 . The method of claim 5 , wherein said CNS damage comprises learning deficits, memory impairment, insomnia, or a personality alteration.
8 . (canceled)
9 . (canceled)
10 . The method of claim 1 , wherein said ASC have been incubated in a 3D culture apparatus.
11 . The method of claim 10 , further comprising harvesting said ASC by removing said ASC from said 3D culture apparatus.
12 . The method of claim 10 , wherein said ASC have been incubated in a 2D adherent-cell culture apparatus, prior to said incubation in a 3D culture apparatus.
13 . The method of claim 10 , wherein said 3D culture apparatus comprises a microcarriers disposed within a bioreactor.
14 . The method of claim 10 , wherein said 3D culture apparatus comprises a synthetic adherent material, wherein said synthetic adherent material is a fibrous matrix.
15 . (canceled)
16 . The method of claim 14 , wherein said synthetic adherent material is selected from the group consisting of a polyester, a polypropylene, a polyalkylene, a polyfluorochloroethylene, a polyvinyl chloride, a polystyrene, a polysulfone, a cellulose acetate, a glass fiber, a ceramic particle, a poly-L-lactic acid, and an inert metal fiber.
17 . (canceled)
18 . The method of claim 1 , wherein said administering comprises:
a. administering to the subject a first pharmaceutical composition, comprising ASC from a first donor; and
b. administering to said subject, at least 7 days after step a), a second pharmaceutical composition comprising allogeneic ASC from a second donor, wherein said second donor differs from said first donor in at least one allele group of human leukocyte antigen (HLA)-A or human leukocyte antigen (HLA)-B,
19 . (canceled)
20 . The method of claim 1 , wherein said ASC originate from placenta tissue.
21 . The method of claim 20 , wherein said ASC express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.
22 . The method of claim 20 , wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD11b, CD14, CD19, and CD34.
23 . The method of claim 20 , wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD34, CD39, and CD106.
24 - 31 . (canceled)
32 . The method of claim 1 , wherein the cells are administered intramuscularly, intravenously, subcutaneously, or intraperitoneally.
33 . (canceled)
34 . The method of claim 1 , wherein the cells are administered intratracheally, intrathecally, by inhalation, or intranasally.